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Irak-4 rs4251481 gene variant: as a risk factor on inflammatory bowel disease
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Background/aim: Abnormal immune response occurs in individuals who have alleles associated with innate and adaptive immune
mechanisms that predispose to inflammatory bowel disease (IBD). Interleukin-1 receptor-associated kinase 4 (IRAK-4) involved in
the pathway produces cytokines that initiate and maintain inflammation through Toll-like receptors and interleukin-1 receptors on the
membranes of innate immune cells are stimulated with antigens. It was aimed to investigate whether IRAK-4 rs3794262 and rs4251481
polymorphisms predispose to IBD and the possible effects of these polymorphisms by examining these gene polymorphisms with the
clinic and prognostic parameters of IBD.
Material and methods: Real-time PCR technique was used to detect IRAK-4 polymorphisms in 107 patients with IBD and 103 healthy
controls.
Results: As a result of experimental studies, the frequency of occurrence of rs4251481 polymorphism related AG genotype (P = 0.029)
and G allele (P = 0.005) was found to increase statistically in patients compared to controls. In the control group, the rs4251481 AA
genotype rate of incidence increased compared with the patient group (P = 0.005).
Conclusion: Consequently, this is the first study in terms of both polymorphisms on IBD. These results suggest that rs4251481 AG
genotype and G allele are associated with increased IBD risk in patients.
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1. Introduction
Inflammatory bowel disease (IBD) is a chronic
autoinflammatory disease that affects the gastrointestinal
tract. It is characterized by abdominal pain, weight loss,
immune cell activation, inflammation, and ulceration (1).
IBD includes Crohn’s disease (CD), ulcerative colitis (UC),
and other conditions (2,3). These two major forms are
characterized by similar patterns although they are distinct
illnesses. UC presents with diffuse mucosal inflammation
involving the rectum and adjacent colonic tissue, and CD
may involve any part of the gastrointestinal tract, from
the mouth to the anus. The etiology of IBD involves many
factors such as genetic inheritance and microbiota (4).
Innate and adaptive immunity-related single nucleotide
polymorphisms (SNPs) are important in the predisposal
to IBD (5).
Interleukin-1 receptor-associated kinase 4 (IRAK4) is one of the elements of the toll-like receptor (TLR)
signal pathway, which plays an important role especially in
innate immunity. The IRAK-4 protein, which is encoded
by the IRAK-4 gene, receives signals from toll-like

receptors and IL-1 receptor-related proteins. As a result
of the stimulation of IL-1R, IL-18R, and many TLRs,
which are first lines defense against infection, the myeloid
differentiation primary response 88 (MyD88) protein is the
first adaptor protein that is connected to the receptors. The
accumulation of IRAK-4 proteins in the area of infection
and the activation of IRAK-4 kinase activity follow this
process (6).
Zhang et al. scanned SNPs in allergic rhinitis for the
IRAK-4 gene and detected a relation between the rs3794262
variant and allergic rhinitis (7). Koziczak-Holbro et al.
demonstrated that IRAK-4 was a key component in the
development of proarthritis inflammation by using mice
devoid of IRAK-4 kinase activity (8). We decided to
examine IRAK-4 rs3794262 (Chr.12: 43771627, intron,
A/T substitution, minor allele frequency = 0.27) and
rs4251481(Chr.12: 43774562, intron, A/G substitution,
minor allele frequency = 0.08) polymorphisms, which
have been studied in a small number of studies.
In this study, we aimed to investigate whether IRAK-4
rs3794262 and rs4251481 polymorphisms predisposed to
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IBD and the possible effects of these polymorphisms by
examining these gene polymorphisms using clinical and
prognostic parameters of IBD.
2. Material and methods
2.1. Subjects
One hundred seven patients with IBD, including 63 with
ulcerative colitis and 44 with Crohn’s disease, who were
admitted to the Department of Gastroenterology between
2016 and 2017, were enrolled in the study. In each patient,
two endoscopic biopsies were taken from different
colonic locations during a colonoscopy examination. The
inclusion criteria for the study groups were based on the
European Crohn’s and Colitis Organization. The control
group, however, consisted of 103 healthy individuals with
a negative history of IBD. All participants gave written
informed consent, and the local ethics committee (Ethics
Committee of İstanbul University, İstanbul Faculty of
Medicine, No: 1751/2015) review board approved the
study protocol.
2.2. DNA Isolation
Genomic DNA was extracted from blood samples using an
Invitrogen PureLink genomic DNA kit .1
2.3. Determination of IRAK-4 SNPs
Genotyping analysis of IRAK-4 SNPs was performed
using real-time polymerase chain reaction (RT-PCR). The
reactions were conducted in final volumes of 20 μL per
patient, containing 10 µL TaqMan® Genotyping Master
Mix, 7.5 µL of dH2O, 1 µL of 20X genotyping assay, 0.5 µL
of TaqMan® probe customized for genotyping of SNPs of
IRAK-4 gene (for SNP ID rs3794262; C__28964290_10 and
for SNP ID rs4251481; C__32291939_10).
Amplification was performed using a fast real-time
PCR system (Applied Biosystems 7500 Fast Instrument,
Waltham, MA, USA) and an Applied Biosystems
StepOnePlus™ instrument (Applied Biosystems, Waltham,
MA, USA), in the following steps: pre-PCR, with a
duration of 1 min at 60 °C; preincubation of the reaction
mixture at 95 °C for 10 min; thermocycling at 95 °C for
15 s and 60 °C for 60 s for 40 cycles; and post-PCR, with a
duration of 1 min at 60 °C.
2.4. Statistical analysis
Categorical variables such as genotypes and alleles
were compared using the chi-square (χ2) test. Allele and
genotype frequencies were determined through direct
counting. Whenever an expected cell value of less than
5 was obtained, Fisher’s exact test was used. Differences
in continuous variables between carriers and the control
subjects were tested using Student’s t-test. Statistical
analyses were performed using the SPSS 21.0 software
(SPSS Inc., Chicago, USA).
1

3. Results
Clinical and demographic parameters are shown in
Table 1. There were no statistical differences between the
study groups according to age (P > 0.05). According to
genotype and allele distribution, there was no relationship
between the rs3794262 genotypes and study groups (P >
0.05). The frequency pattern of rs4251481 AG genotype
(95% CI: [1.15–15.38]; P = 0.029) and G allele (95% CI:
[1.52–19.38]; P = 0.005) in all patients was statistically
significant compared with the control group. In addition,
the rs4251481 AA genotype was observed at a significantly
greater frequency in the control group than in all patients
in the study (95% CI: [0.05–0.65]; P = 0.005). However, no
association was found between IRAK-4 variants and the
UC and CD groups (Table 2).
Similar to the comparison between all patients and
the control group, the frequencies of the rs4251481 AG
genotype (95% CI: [1.25–22.11]; P = 0.021) and G allele
(95% CI: [1.54–25.67]; P = 0.008) were greater in the CD
group than in the control group. In the UC group, only the
rs4251481 G allele was observed as a risk factor for disease
(95% CI: [1.23–19.02]; P = 0.022). The frequency of the
rs4251481 AA genotype was greater in the control group
compared with the UC group (95% CI: [0.05–0.80]; P =
0.022) (Table 2).
No significant relationship was found between gene
variants and clinical/demographic parameters in the
patient groups. However, although C-reactive protein
(CRP) levels were within the reference range (0–5 mg/L),
patients with UC who carried the IRAK-4 rs4251481 GG
genotype had increased CRP (AA = 1.10 ± 3.60; AG = 0.36
± 0.26; GG = 1.25 ± 0.63) and erythrocyte sedimentation
rates (mm/h) (AA = 26.30 ± 20.19; AG = 33.00 ± 25.82;
GG = 38.00 ± 1.14) compared with AG and AA, but the
differences were not significant.
4. Discussion
IBD is a chronic and complex genetic disease. Although
the role of microbial factors, bacterial clearance defects,
and immune response defects are known, the etiologies of
IBD are not yet well understood (9).
IRAK-4 gene interacts with MyD88, which leads
to the activation of nuclear factor-κb (NF-κB) and the
transcription of inflammatory mediators. It was reported
that in IRAK-4 knock-out rats that many TLR ligands
and intracellular IL-1, IL-18 responses were extreme
(10). Kondo et al. suggested that AS2444697, which is an
IRAK-4 inhibitor, suppressed the progression of chronic
renal failure via antiinflammatory action and might be
potentially useful in treating patients with chronic kidney
disease (11).

https://www.thermofisher.com/order/catalog/product/K182001 (online access: 23.10 2018)
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Table 1. Clinical and demographical parameters of the study groups.
Clinical parameters

All patients
(n=107)

UC
(n=63)

CD
(n=44)

Controls
(n=103)

P-value

Age (year)

43.77 ± 13.63

45.71 ± 14.90

40.98 ± 10.30

44.33 ± 13.88

>0.05

Sex (male/emale)

53/54

30/33

23/21

50/53

-

C-reactive protein (mg/L)
(reference range 0–5 mg/L)

1.08 ± 2.82

1.03 ± 3.36

1.14 ± 1.85

0.49 ± 1.15

>0.05

Erythrocyte sedimentation
range (mm/h)

27.08 ± 20.27

27.34 ± 20.49

26.70 ± 20.19

28.80 ± 11.43

>0.05

Demographical
parameters

UC
(n=63)

CD
(n=44)

Disease extension in UC
Proctitis (n/%)
Left-sided colitis (n/%)
Extensive colitis (n/%)

30/48.4
15/24.2
17/27.4

-

Disease localization
Ileal (n/%)
Ileocolonic (n/%)
Colonic (n/%)

-

20/45.5
20/45.5
4/9

Disease behavior
Inflammatory (n/%)
Penetrating (n/%)
Structuring (n/%)
Penetrating and structuring (n/%)

-

21/48.8
8/18.6
13/30.2
1/ 2.3

n = number of subjects, UC = ulcerative colitis, CD = Crohn’s disease.

Table 2. Distribution of the IRAK-4 rs4251481 and rs3794262 gene variants in the study groups.
IRAK-4 rs4251481

All patients
(n=107)

UC
(n=63)

CD
(n=44)

Controls
(n=103)

AA (n/%)

92/86

55/87.3

37/84.1

100/97.1*,***

GG (n/%)

3/2.8

2/3.2

1/2.3

-

AG (n/%)

12/11.5*

6/9.5

6/13.6**

3/2.9

A (n/%)

196/91.5

116/92.1

80/90.9

203/98.5

G (n/%)

18/8.5*

10/7.9***

8/9.1**

3/1.5

IRAK-4 rs3794262

All patients
(n=107)

UC
(n=63)

CD
(n=44)

Controls
(n=103)

TT (n/%)

80/74.8

47/74.6

33/75

81/78.6

AA (n/%)

2/1.9

2/3,2

-

-

TA (n/%)

25/23.4

14/22.2

11/25

22/21.4

T (n/%)

185/86.4

108/85.7

77/87.5

184/89.3

A (n/%)

29/13.6

18/14.3

11/12.5

22/10.7

n = number of subjects, UC = ulcerative colitis, CD = Crohn’s disease, * all patients vs control, for AG genotype
P = 0.029; for G allele P = 0.005; for AA P = 0.005 ** CD vs control, for AG genotype P = 0.021; for G allele P =
0.008 *** UC vs control, for G allele P = 0.022; for AA P = 0.022.
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As a result of a literature review, it was seen that there
are a limited number of studies on IRAK-4 and IBD, which
is an important pathway of this route. For this reason, the
purpose of our study was to determine the efficiency of
IRAK-4 gene variants, which has not previously been
investigated in IBD.
In the present study, we found no association between
IRAK-4 rs3794262 genotypes and the study groups.
However, there was a remarkable difference regarding
IRAK-4 rs4251481 genotypes between the study groups.
The difference in frequency of the rs4251481 AG genotype
(P = 0.029) and the G allele (P = 0.005) in all patients was
statistically significant compared with the control group.
Also, in the CD group, the frequencies of the rs4251481
AG genotype (P = 0.021) and the G allele (P=0.008) were
greater than in the control group. In the UC group, only
the rs4251481 G allele was observed as a risk factor for
disease (P = 0.022).
Zhang et al. reported that two SNPs (rs3794262,
rs4251481) showed a strong association with allergic
rhinitis in patients who were allergic to house dust mites,
but not in patients allergic to pollens or mixed allergens (7).
No functional effects of these IRAK-4 SNPs on the gene
function such as inhibition or activation were observed.
However, our results confirm this positive association
between IRAK-4 genotypes and IBD as an inflammatory
disease.
There were no statistically significant relationships
between demographic parameters and IRAK-4 genotypes
in the UC and CD groups (P > 0.05). Furthermore, we
observed no differences between the patients and controls

in terms of biochemical parameters. However, patients
with UC who carried IRAK-4 rs4251481 GG genotype
had increased CRP and sedimentation rates compared
with AG and AA, albeit nonsignificantly. Our results are
similar to our genotyping results, which showed that the
G allele is a risk factor for UC and the AA genotype is a
protective genotype against UC. Some studies showed that
CRP and erythrocyte sedimentation rates were important
for the diagnosis and determination of clinical activity of
IBD (12–14). CRP may be a useful predictor of surgery in
subgroups of patients with either UC or Crohn’s disease.
It was demonstrated by Sachar et al. that the rate of
increase in sedimentation range with progressively
increasing clinical activity from mild to moderate was
the same in all disease categories, with the exception of
Crohn’s disease (13). Henriksen et al. indicated that CRP
levels at diagnosis were related to the extent of disease in
patients with UC (14).
There are some limitations of this study, one of which
is the relatively small size of the study population. Another
limitation is that we could not use any other techniques,
such as ELISA for IRAK-4, to support our results.
To our knowledge, this is the first study to suggest
that the association of the AG genotype and G allele of
rs4251481 variants in the IRAK-4 gene with susceptibility
to IBD.
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